Emens, L. A., Adams, S., Barrios, C. H., Diéras, V., Iwata, H., Loi, S., . . . Schmid, P. (2021). Corrigendum to "First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis": Annals of Oncology 2021; volume 32: 983-993. Annals of oncology, 32(10), . https://doi.org/10.1016/j.annonc.2021.07.013
Chicago-Zitierstil (17. Ausg.)Emens, Leisha Ann, et al. "Corrigendum to "First-line Atezolizumab Plus Nab-paclitaxel for Unresectable Locally Advanced or Metastatic Triple-negative Breast Cancer: IMpassion130 Final Overall Survival Analysis": Annals of Oncology 2021; Volume 32: 983-993." Annals of Oncology 32, no. 10 (2021). https://doi.org/10.1016/j.annonc.2021.07.013.
MLA-Zitierstil (9. Ausg.)Emens, Leisha Ann, et al. "Corrigendum to "First-line Atezolizumab Plus Nab-paclitaxel for Unresectable Locally Advanced or Metastatic Triple-negative Breast Cancer: IMpassion130 Final Overall Survival Analysis": Annals of Oncology 2021; Volume 32: 983-993." Annals of Oncology, vol. 32, no. 10, 2021, https://doi.org/10.1016/j.annonc.2021.07.013.